论文部分内容阅读
Objective: We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer(SCLC). Methods: From October 2011 to November 2013, 32 elderly patients(71–79 years old) with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region(China) were enrolled in the research. The patients were administrated with lastet capsule 150–175 mg, d1–5, combined with cisplatin 20 mg/m2 d1–3 or carboplatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results: After treatments, 2 cases acquired complete response(CR), 19 cases acquired partial response(PR), 8 cases acquired stable disease(SD), and 3 cases had progression of disease(PD). The objective response rate was 65.6%(21/32), disease control rate was 90.6%(29/32). The median time of progression-free survival(PFS) was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of I/II leukopenia and gastrointestinal reaction were observed. Conclusion: Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC.
Objective: We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer (SCLC). Methods: From October 2011 to November 2013, 32 elderly patients (71-79 years old) with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region (China) were enrolled in the research. The patients were administrated with lastet capsule 150-175 mg, d1-5, combined with cisplatin 20 mg / m2 d1-3 or carboplatin Twenty-one days were 1 treatment cycle. Results: After treatments, 2 cases acquired complete response (CR), 19 cases acquired partial response (PR), 8 cases acquired stable disease (SD), The objective response rate was 65.6% (21/32), the disease control rate was 90.6% (29/32). The median time of progression-free survival (PFS) was 6.9 months , the median survival time was 14.0 months, and 1 year survival rat e was 62.4%. The main adverse reactions of I / II leukopenia and gastrointestinal reaction were observed. Conclusion: Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC.